Focus instead on individual compounds with actual evidence: Most evidence-based options: Berberine (1,000-1,500mg daily): For metabolic syndrome support, insulin sensitivity improvement, modest glucose and lipid benefits Fiber supplements (25-38g daily total from food and supplements): For satiety, gut health, and transient GLP-1 increases Product selection criteria: Transparent ingredient amounts (no proprietary blends) Research-supported dosing Third-party testing certifications (USP, NSF, Informed Choice) Realistic marketing without pharmaceutical comparisons Rather than choosing based on GLP-1 booster labels, select evidence-based compounds appropriate to your specific metabolic needs

Single and dual agonists The fundamental difference between these two molecules is that semaglutide is a GLP-1 agonist, i.e., it has a strong structural similarity (95%) with this hormone and specifically activates its receptor, while tirzepatide is a dual agonist, i.e., it has a hybrid structure that allows it to activate both GLP-1 and GIP receptors (Figure 2)
Q: What peptide is similar to tirzepatide
Different patient populations, different enrollment criteria, different sites, and different measurement protocols all introduce variability that makes direct numerical comparison imprecise